Oncaspar 750 Unit

ONCASPAR 750 Unit is a pegylated asparaginase solution used in cancer treatment. This intramuscular injection is manufactured by Servier Canada Inc. and is available in a 5ml pack size.

ONCASPAR 750 Unit is primarily used in the treatment of acute lymphoblastic leukemia (ALL). This medication works by reducing the levels of asparagine in the body, which certain cancer cells need to grow. It is often used as part of a combination chemotherapy regimen. Patients should consult their healthcare provider to determine if this medication is suitable for their specific condition.

Common effects of ONCASPAR 750 Unit may include injection site reactions, nausea, vomiting, and allergic reactions. Some patients may experience changes in blood cell counts or liver function. It is important to monitor for any signs of an allergic reaction, such as rash, itching, or difficulty breathing, and seek medical attention if these occur.

ONCASPAR 750 Unit should be handled with care and administered by a healthcare professional. It is important to inform your healthcare provider about any allergies or medical conditions before starting this treatment. Pregnant or breastfeeding women should discuss the potential risks and benefits with their doctor. Always follow the storage and handling instructions provided with the medication.

ONCASPAR 750 Unit may interact with other medications, including those that affect the immune system or blood clotting. It is important to inform your healthcare provider about all medications you are taking, including prescription, over-the-counter, and herbal products. Alcohol and certain foods may also interact with this medication, so it is advisable to discuss any dietary restrictions with your doctor.